Editorial: Let the science decide on plioglitazone

That the Union Health Ministry takes critical decisions affecting a large number of people without any scientific basis does not portend well for public health in India. Neither the ban imposed on the oral anti-diabetes drug pioglitazone on June 18 nor its revocation a month later with a requirement that the medicine be sold with … Continue reading Editorial: Let the science decide on plioglitazone

Drugs board wants ban on Pioglitazone diabetes drug revoked

The Drugs Technical Advisory Board (DTAB) on Friday recommended revoking the ban on pioglitazone — an oral anti-diabetic drug which was banned on June 18. But the DTAB, which was kept in the dark when the decision to ban was taken, has also recommended that the medicine be sold with a boxed warning (that the … Continue reading Drugs board wants ban on Pioglitazone diabetes drug revoked

Pioglitazone: no bladder cancer for 3 years

A three-year study (2005-2008) undertaken on 204 subjects who had impaired glucose tolerance (IGT), a pre-diabetic stage, and who were on pioglitazone drug alone did not find any case of bladder cancer. The primary objective was, however, to see if the drug in addition to lifestyle modifications helped in preventing subjects with IGT from becoming … Continue reading Pioglitazone: no bladder cancer for 3 years

Diabetes drug: ‘Maybe I erred in my judgement’

There is growing evidence that the ban the Union Health Ministry imposed on June 18 on pioglitazone — a widely used anti-diabetes oral drug — was taken with undue haste and in great secrecy. There was no large-scale scientific study undertaken to know the risk of bladder cancer caused by the drug before imposing the … Continue reading Diabetes drug: ‘Maybe I erred in my judgement’